

December 2020



### **MSD Animal Health Brexit statement**

MSD Animal Health is a market leader in the provision of veterinary pharmaceuticals, vaccines and health management solutions in the UK. Since the outcome of the EU referendum we have been working to ensure continuity of supply under all scenarios, including a scenario where no trade deal is reached by the end of the transition period (31 December 2020).

To mitigate any disruption associated with the end of the transition period, we have put in place measures to safeguard availability of products, which include building stock in the supply chain, secured ferry crossings and customs brokerage. We have also reconfigured our commercial distribution routes to avoid as best as possible any delays and disruptions at UK ports and borders and we now avoid the Dover to Calais short strait for both UK/EU inbound and outbound shipments.

Throughout this planning process we have followed and applied the recommendations contained within the preparedness notices published by the UK Government and the European Commission. This has involved regular dialogue with the relevant national regulatory bodies and agencies.

We are confident that our contingency plans across our business have been implemented effectively and will help to ensure that MSD Animal Health does not experience any disruption to continuity of supply as a consequence of the end of the transition period.

Like all pharmaceutical companies, MSD Animal Health does have supply constraints on products from time to time. These are entirely unrelated to the end of the transition period and we have standard procedures in place to ensure customers and regulators are aware of any potential supply issues as early as possible.